Skip to Main content Skip to Navigation
Journal articles

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

Abstract : Cancer therapy is currently shifting from broadly used cytotoxic drugs to patient-specific precision therapies. Druggable driver oncogenes, identified by molecular analyses, are present in only a subset of patients. Functional profiling of primary tumor cells could circumvent these limitations, but suitable platforms are unavailable for most cancer entities. Here, we describe an in vitro drug profiling platform for rhabdomyosarcoma (RMS), using a living biobank composed of twenty RMS patient-derived xenografts (PDX) for high-throughput drug testing. Optimized in vitro conditions preserve phenotypic and molecular characteristics of primary PDX cells and are compatible with propagation of cells directly isolated from patient tumors. Besides a heterogeneous spectrum of responses of largely patient-specific vulnerabilities, profiling with a large drug library reveals a strong sensitivity towards AKT inhibitors in a subgroup of RMS. Overall, our study highlights the feasibility of in vitro drug profiling of primary RMS for patient-specific treatment selection in a co-clinical setting.
Complete list of metadata

Cited literature [47 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02958175
Contributor : Myriam Bodescot <>
Submitted on : Monday, October 5, 2020 - 4:24:24 PM
Last modification on : Saturday, April 3, 2021 - 3:22:09 AM

File

s41467-020-18388-7.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Gabriele Manzella, Leonie Schreck, Willemijn Breunis, Jan Molenaar, Hans Merks, et al.. Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4629. ⟨10.1038/s41467-020-18388-7⟩. ⟨inserm-02958175⟩

Share

Metrics

Record views

103

Files downloads

104